噻托溴铵治疗慢性阻塞性肺疾病研究进展

Research progress of management of chronic obstructive pulmonary disease with tiotropium

噻托溴铵是一种新型的胆碱能Ms受体阻断剂，长期每天吸入1次（18μg）可有效地改善稳定期慢性阻塞性肺疾病（chronic obstructive pulmonary disease，COPD）患者的肺功能，减少呼气末气体陷闭，减少动态肺过度充气，缓解呼吸困难，从而可以进一步改善其生存和生活质量，减少急性发作的次数，推迟急性发作出现的时间，减少患者的住院天数。噻托溴铵为稳定期COPD患者的治疗提供了新的手段。

Tiotropium is a new long-acting Ms blocker for the treatment of patients with chronic obstructive pulmonary disease（COPD）. The long-term inhaling of tiotropium, 18 μg per day,may effectively improve the lung function of COPD patients,lesson the air trap at the end of expiration, relieve the dynamic lung hyperinflation and exertion dyspnea. All these efficacies will lead to the improvement of life quality of the patients,reduction of the acute onset event of the patients, delaying the occurring of exacerbation and lessening the days of hospitalization. Tiotropium provides a new therapy in the management of patients with COPD.